Physician profile
Bashar A Mohsen
NPI 1114953650
$2,795.41
in general payments reported to CMS, 2019-2025
23 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.58 · 2022: $62.62 · 2023: $351 · 2024: $846 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,638 · Education: $79.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.36 |
| Education | $79.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $466.45 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $419.95 | 2024-2025 | Purified Cortrophin Gel |
| Abbvie INC. | $299.40 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $267.72 | 2024-2025 | Acthar |
| Argenx US, INC. | $231.23 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $203.26 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Pfizer INC. | $195.01 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $148.62 | 2023-2025 | |
| Sk Life Science, INC. | $108.73 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $72.54 | 2025 | Rexulti |
| Genentech USA, INC. | $58.36 | 2025 | Ocrevus Zunovo |
| Neurelis, INC. | $54.35 | 2021-2023 | Valtoco |
| Mdd US Operations, LLC | $44.04 | 2024-2025 | Apokyn |
| Ucb, INC. | $39.80 | 2024 | Nayzilam |
| Celgene Corporation | $39.72 | 2022-2025 | Zeposia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $32.55 | 2022-2024 | Ultomiris |
| Lilly USA, LLC | $24.13 | 2023 | Amyvid |
| Janssen Pharmaceuticals, INC | $21.78 | 2023 | Ponvory |
| Impel Pharmaceuticals INC. | $18.94 | 2023 | Trudhesa |
| Banner Life Sciences, LLC | $18.52 | 2022 | |
| Merz Pharmaceuticals, LLC | $16.81 | 2025 | Xeomin, Inbrija |
| Supernus Pharmaceuticals, INC. | $13.50 | 2025 | Qelbree |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Mohsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.